ARTICLE | Company News
Ontogen news
January 14, 2002 8:00 AM UTC
Ontogen received a $1.3 million Phase II SBIR from the National Institute of Diabetes and Digestive and Kidney Diseases to develop inhibitors of the enzyme fructose-1,6-bisphosphatase (FBPase), which ...